Mechanisms of altered cell immunity and cytotoxicity in COPD

Current Drug Targets

Volumn 12, Issue 4, 2011, Pages 450-459

  Tsoumakidou, M ^a   Tsiligianni, I ^b   Tzanakis, N ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Adaptive; Chronic obstructive pulmonary disease; Cigarette smoke; Innate; Pathogenesis

Indexed keywords

ANTIOXIDANT; CIGARETTE SMOKE; INFLIXIMAB; OXIDIZING AGENT; PROTEINASE; TISSUE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BRONCHUS MUCOSA; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EPITHELIUM CELL; HELPER CELL; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; NEUTROPHIL; NONHUMAN; RESPIRATORY TRACT INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; SMOKING;

EID: 79952740357     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794751546     Document Type: Article

References (122)

1. Jeffery PK, Li D. Airway mucosa: secretory cells, mucus and mucin genes. Eur Respir J 1997; 10: 1655-1662.
2. Reid L. Measurement of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax 1960; 15: 132-1341.
3. Davies JR, Hovenberg HW, Linden CJ, et al. Mucins in airway secretions from healthy and chronic bronchitic subjects. Biochem J 1996; 313 (Pt 2): 431-439.
4. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8:1333-1338.
5. Riise GC, Andersson B, Ahlstedt S, et al. Bronchial brush biopsies for studies of epithelial inflammation in stable asthma and nonobstructive chronic bronchitis. Eur Respir J 1996; 9: 1665-1671.
6. Trevisani L, Sartori S, Pazzi P, et al. Acquired ciliary defects in bronchial epithelium of patients with chronic bronchitis. Respiration 1990; 57: 6-13.
7. Verra F, Escudier E, Lebargy F, Bernaudin JF, De Cremoux H, Bignon J. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med 1995;151: 630-634.
8. McDowell EM, Barrett LA, Harris CC, Trump BF. Abnormal cilia in human bronchial epithelium. Arch Pathol Lab Med 1976; 100: 429-436.
9. Adler KB, Hendley DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol 1986; 125: 501-514.
10. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest 2000; 117: 286S-91S.
11. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
12. Speizer FE, Fay ME, Dockery DW, Ferris BG, Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis 1989; 140: S49-55.
13. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535.
14. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45: 579-585.
15. Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1,061 working men. Am Rev Respir Dis 1986; 134: 688-693.
16. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
17. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
18. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002; 20: 825-852.
19. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007; 220: 251-269.
20. Guillot L, Medjane S, Le-Barillec K, et al. Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem 2004; 279: 2712-2718.
21. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168: 5989-5992.
22. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029.
23. Ganz T. Immunology. Versatile defensins. Science 2002; 298: 977-979.
24. Doz E, Noulin N, Boichot E, et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 2008; 180: 1169-1178.
25. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-298.
26. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 2000; 173: 27-38.
27. Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. Am J Respir Cell Mol Biol 2006; 35: 314-319.
28. Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001; 163: 1476-1483.
29. Thorley AJ, Tetley TD. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007; 2: 409-428.
30. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998; 78: 1077-1087.
31. Barnes PJ. Alveolar macrophages as orchestrators of COPD. Copd 2004; 1: 59-70.
32. Birrell MA, Wong S, Catley MC, Belvisi MG. Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages. J Cell Physiol 2008; 214: 27-37.
33. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 968-975.
34. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409.
35. Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005; 289: L322-328.
36. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009; 121: 55-68.
37. Miller AL, Strieter RM, Gruber AD, Ho SB, Lukacs NW. CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J Immunol 2003; 170: 3348-3356.
38. Costa C, Rufino R, Traves SL, Lapa ESJR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008; 133: 26-33.
39. Hardaker EL, Bacon AM, Carlson K, et al. Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease. FASEB J 2004; 18: 191-193.
40. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117: 684-694.
41. Molet S, Belleguic C, Lena H, et al. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res 2005; 54: 31-36.
42. Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005; 6: 151.
43. Bracciale P, Bellanova S, Gastagnaro A, Scoditti C, Valerio G. Alveolar macrophage activity and its correlation with burden of reactive oxygen species in bronchoalveolar fluid and in the serum of patients affected by chronic obstructive pulmonary disease III- IV GOLD stage. Chest 2009; 136: 175-181.
44. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000; 80: 617-653.
45. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109-115.
46. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
47. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152: 1926-1931.
48. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285.
49. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002; 121: 151S-5S.
50. Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science 1979; 206: 1315-1316.
51. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009; 34: 475-488.
52. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999; 276: L835-843.
53. Takeyama K, Agusti C, Ueki I, Lausier J, Cardell LO, Nadel JA. Neutrophil-dependent goblet cell degranulation: role of membrane- bound elastase and adhesion molecules. Am J Physiol 1998; 275: L294-302.
54. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478-1484.
55. Zhou H, Alexis NE, Almond M, et al. Influence of C-159T SNP of the CD14 gene promoter on lung function in smokers. Respir Med 2009; 103: 1358-1365.
56. Stockley RA. Proteases and antiproteases. Novartis Found Symp 2001; 234: 189-199; discussion 99-204.
57. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997; 277: 2002-2004.
58. Bartels CL, Marchetti AL, Edward Highsmith W, Tsongalis GJ. Real time PCR detection of the PI*Z and PI*S mutations associated with alpha-1 antitrypsin deficiency. Am J Transl Res 2009; 1: 406-411.
59. Taggart C, Cervantes-Laurean D, Kim G, et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000; 275: 27258-27265.
60. Parameswaran GI, Wrona CT, Murphy TF, Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease- antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009; 9: 178.
61. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002; 283: L867-873.
62. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metallo- proteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609.
63. Loukidis S, Bakakos P, Kostikas K. Oxidative stress in patients with COPD. Curr Drug Targets 2011; 12(4): 469-477.
64. Eiserich JP, Vossen V, O'Neill CA, Halliwell B, Cross CE, van der Vliet A. Molecular mechanisms of damage by excess nitrogen oxides: nitration of tyrosine by gas-phase cigarette smoke. FEBS Lett 1994; 353: 53-56.
65. Cross CE, van der Vliet A, O'Neill CA, Eiserich JP. Reactive oxygen species and the lung. Lancet 1994; 344: 930-933.
66. Rahman I. The role of oxidative stress in the pathogenesis of OPD: implications for therapy. Treat Respir Med 2005; 4: 175-200.
67. MacNee W. Pulmonary and systemic oxidant/antioxidant mbalance in chronic obstructive pulmonary disease. Proc Am horac Soc 2005; 2: 50-60.
68. Janssen LJ. Isoprostanes: an overview and putative roles in ulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 001; 280: L1067-82.
69. Kostikas K, Koutsokera A, Papiris S, Gourgoulianis KI, Loukides. Exhaled breath condensate in patients with asthma: implications or application in clinical practice. Clin Exp Allergy 2008; 38: 557-565.
70. Kharitonov SA, Barnes PJ. Exhaled biomarkers. Chest 2006; 130: 1541-1546.
71. Gotoh Y, Cooper JA. Reactive oxygen species- and dimerization- induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem 1998; 273: 17477-174782.
72. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6: 205-217.
73. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
74. van der Strate BW, Postma DS, Brandsma CA, et al. Cigarette Smoke-induced Emphysema: A Role for the B Cell? Am J Respir Crit Care Med 2006; 173: 751-758.
75. Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009; 34: 219-2130.
76. Sullivan AK, Simonian PL, Falta MT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005; 172: 590-596.
77. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8 T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
78. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
79. Chrysofakis G, Tzanakis N, Kyriakoy D, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 2004; 125: 71-76.
80. Vernooy JH, Moller GM, van Suylen RJ, et al. Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 464-472.
81. Maeno T, Houghton AM, Quintero PA, Grumelli S, Owen CA, Shapiro SD. CD8 T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol 2007; 178: 8090-8096.
82. Barcelo B, Pons J, Fuster A, et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006; 145: 474-479.
83. Barczyk A, Pierzchala W, Kon OM, Cosio B, Adcock IM, Barnes PJ. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006; 117: 1484-1492.
84. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004; 1: e8.
85. Hodge G, Nairn J, Holmes M, Reynolds PN, Hodge S. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin Exp Immunol 2007; 150: 22-29.
86. Freeman CM, Curtis JL, Chensue SW. CC Chemokine Receptor 5 and CXC Chemokine Receptor 6 Expression by Lung CD8+ Cells Correlates with Chronic Obstructive Pulmonary Disease Severity. Am J Pathol 2007; 171: 767-776.
87. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-855.
88. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337-348.
89. Di Stefano A, Caramori G, Capelli A, et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 78-85.
90. Smyth LJ, Starkey C, Vestbo J, Singh D. CD4-regulatory cells in COPD patients. Chest 2007; 132: 156-163.
91. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
92. Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 2009; 157: 316-324.
93. Harrison OJ, Foley J, Bolognese BJ, Long E 3rd, Podolin PL, Walsh PT. Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. Immunol Lett 2008; 121: 13-21.
94. Melgert BN, Timens W, Kerstjens HA, et al. Effects of 4 months of smoking in mice with ovalbumin-induced airway inflammation. Clin Exp Allergy 2007; 37: 1798-1808.
95. Gosman MM, Willemse BW, Jansen DF, et al. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J 2006; 27: 60-64.
96. Zhu J, Qiu Y, Valobra M, et al. Plasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1125-1133.
97. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 156-163.
98. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007; 37 (Suppl 1): S53-60.
99. Demedts IK, Bracke KR, Van Pottelberge G, et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 998-1005.
100. Tsoumakidou M, Jeffery PK. Dendritic cell maturity and obstructive airway disease. Am J Respir Crit Care Med 2007; 176: 833; author reply -4.
101. Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 1179-1188.
102. Demedts IK, Brusselle GG, Vermaelen KY, Pauwels RA. Identification and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol 2005; 32: 177-184.
103. Tsoumakidou M, Koutsopoulos AV, Tzanakis N, et al. Decreased small airway and alveolar CD83+ dendritic cells in COPD. Chest 2009; 136: 726-733.
104. Tsoumakidou M, Bouloukaki I, Koutala H, et al. Decreased sputum mature dendritic cells in healthy smokers and patients with chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2009; 150: 389-397.
105. Tsoumakidou M, Demedts IK, Brusselle GG, Jeffery PK. Dendritic cells in chronic obstructive pulmonary disease: new players in an old game. Am J Respir Crit Care Med 2008; 177: 1180-1186.
106. Robbins CS, Dawe DE, Goncharova SI, et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol 2004; 30: 202-211.
107. Robbins CS, Franco F, Mouded M, Cernadas M, Shapiro SD. Cigarette smoke exposure impairs dendritic cell maturation and T cell proliferation in thoracic lymph nodes of mice. J Immunol 2008; 180: 6623-6628.
108. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 2005; 175: 2684-2691.
109. Mortaz E, Kraneveld AD, Smit JJ, et al. Effect of cigarette smoke extract on dendritic cells and their impact on T-cell proliferation. PLoS One 2009; 4: e4946.
110. Francus T, Klein RF, Staiano-Coico L, Becker CG, Siskind GW. Effects of tobacco glycoprotein (TGP) on the immune system. II. TGP stimulates the proliferation of human T cells and the differentiation of human B cells into Ig secreting cells. J Immunol 1988; 140: 1823-1829.
111. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
112. Nseir S, Ader F, Lubret R, Marquette C-H. Pathophysiology of airway colonization in critically ill patients. Curr Drug Targets 2011; 12(4): 514-520.
113. Sethi S, Wrona C, Grant BJ, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448-453.
114. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
115. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004; 170: 408-413.
116. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
117. Gadgil A, Duncan SR. Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 531-541.
118. Taraseviciene-Stewart L, Scerbavicius R, et al. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005; 171: 734-742.
119. Lee SJ, Chinen J, Kavanaugh A. Immunomodulator therapy: mono-clonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol 2010; 125: S314-323.
120. Rennard SI, Fogarty C, Kelsen S, et al. on behalf of the COPD Investigators: The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-934.
121. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD* a pilot study. Chest 2004; 126: 926-934
122. Barnes PJ. Emerging Pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.